JP6781045B2 - アッセイ及び薬剤 - Google Patents

アッセイ及び薬剤 Download PDF

Info

Publication number
JP6781045B2
JP6781045B2 JP2016546969A JP2016546969A JP6781045B2 JP 6781045 B2 JP6781045 B2 JP 6781045B2 JP 2016546969 A JP2016546969 A JP 2016546969A JP 2016546969 A JP2016546969 A JP 2016546969A JP 6781045 B2 JP6781045 B2 JP 6781045B2
Authority
JP
Japan
Prior art keywords
rna
virus
segment
influenza
segments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016546969A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017504331A (ja
JP2017504331A5 (enExample
Inventor
ジェイ． ディモック，ナイジェル
ジェイ． ディモック，ナイジェル
ジェイ． イーストン，アンドリュー
ジェイ． イーストン，アンドリュー
Original Assignee
ザ ユニバーシティ オブ ウォリック
ザ ユニバーシティ オブ ウォリック
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ユニバーシティ オブ ウォリック, ザ ユニバーシティ オブ ウォリック filed Critical ザ ユニバーシティ オブ ウォリック
Publication of JP2017504331A publication Critical patent/JP2017504331A/ja
Publication of JP2017504331A5 publication Critical patent/JP2017504331A5/ja
Application granted granted Critical
Publication of JP6781045B2 publication Critical patent/JP6781045B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16162—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2016546969A 2014-01-16 2015-01-16 アッセイ及び薬剤 Active JP6781045B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1400752.0 2014-01-16
GB1400752.0A GB2522615A (en) 2014-01-16 2014-01-16 Assay and medicament
PCT/GB2015/050094 WO2015107357A1 (en) 2014-01-16 2015-01-16 Assay and medicament

Publications (3)

Publication Number Publication Date
JP2017504331A JP2017504331A (ja) 2017-02-09
JP2017504331A5 JP2017504331A5 (enExample) 2018-02-22
JP6781045B2 true JP6781045B2 (ja) 2020-11-04

Family

ID=50239057

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016546969A Active JP6781045B2 (ja) 2014-01-16 2015-01-16 アッセイ及び薬剤

Country Status (8)

Country Link
US (3) US20160333321A1 (enExample)
EP (2) EP4085917A1 (enExample)
JP (1) JP6781045B2 (enExample)
DK (1) DK3094338T3 (enExample)
ES (1) ES2913063T3 (enExample)
GB (1) GB2522615A (enExample)
PL (1) PL3094338T3 (enExample)
WO (1) WO2015107357A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4046689A1 (en) * 2021-02-18 2022-08-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Influenza virus defective interfering particles for use in the prophylactic or therapeutic treatment of coronaviridae infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0408424D0 (en) * 2004-04-15 2004-05-19 Univ Warwick Viral assay
NZ555118A (en) * 2004-11-11 2009-09-25 Solvay Biologicals Bv Defective influenza virus particles incapable of producing functional polymerase
US8435508B2 (en) * 2006-05-24 2013-05-07 The University Of Warwick Cloned defective interfering influenza A virus
GB2437799B (en) * 2006-05-24 2008-08-13 Univ Warwick Defective interfering virus
GB0822672D0 (en) * 2008-12-12 2009-01-21 Univ Warwick Anti-viral protection with viruses containing a defective genome
US20130156733A1 (en) * 2011-12-20 2013-06-20 Philip I. Marcus Influenza virus populations, methods of use and methods of making thereof

Also Published As

Publication number Publication date
WO2015107357A1 (en) 2015-07-23
ES2913063T3 (es) 2022-05-31
GB201400752D0 (en) 2014-03-05
EP3094338A1 (en) 2016-11-23
US11339374B2 (en) 2022-05-24
DK3094338T3 (da) 2022-05-23
US20200231939A1 (en) 2020-07-23
PL3094338T3 (pl) 2022-08-08
GB2522615A (en) 2015-08-05
US20220325251A1 (en) 2022-10-13
EP4085917A1 (en) 2022-11-09
JP2017504331A (ja) 2017-02-09
US20160333321A1 (en) 2016-11-17
EP3094338B1 (en) 2022-04-13

Similar Documents

Publication Publication Date Title
US12410409B2 (en) Influenza viruses with mutant PB2 gene segment as live attenuated vaccines
Marriott et al. Defective interfering viruses and their potential as antiviral agents
US6974686B2 (en) Recombinant tryptophan mutants of influenza
US11180737B2 (en) Generation of infectious influenza viruses from virus-like particles
WO2008147496A2 (en) Neuraminidase-deficient live influenza vaccines
JPH11507510A (ja) インフルエンザの新規組換え温度感受性変異体
Meng et al. Unexpected complexity in the interference activity of a cloned influenza defective interfering RNA
Wu et al. A live bivalent influenza vaccine based on a H9N2 virus strain
US20220325251A1 (en) Assay and medicament
Abbas et al. Proteins of Influenza Virus: A Review
US9119810B2 (en) Compositions and vaccines against influenza A and influenza B infections
US10272149B2 (en) Modified bat influenza viruses and their uses
Wu et al. Characterization of influenza A virus with nine segments: Effect gene segment on virus property
Abbas Special Issues
Feder Internal viral RNA sequences of the PB2 genome segment of influenza A virus are required for efficient generation of fully infectious particles
Turnbull Role of the NS segment of Influenza A virus in setting host range and pathogenicity
Moreira Bat influenza viruses: insights in the molecular biology and characterization of infectious viruses
Won Reverse genetics system and fucntion of NSM protein of Rift Valley fever virus (family Bunyaviridae, genus phlebovirus)
Atasheva Finding a cure for Venezuelan equine encephalitis virus infection: The search for antiviral genes and vaccine development

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20161118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180112

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200422

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200915

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201015

R150 Certificate of patent or registration of utility model

Ref document number: 6781045

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250